Sale of Clinical Lab

Novacyt continues to focus on driving value from its core businesses

Paris, France and Camberley, UK – 18 July 2019Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces it has completed the sale of its clinical laboratory business (the “Clinical Lab”) to Cambridge Pathology BV (the “Buyer”) for a total consideration of £400,000. This sale will enable Novacyt to focus more closely on the expansion and value of its core businesses, Primerdesign and Lab21.

https://novacyt.com/wp-content/uploads/2019/07/Novacyt-sale-of-Lab21-clinical-laboratory-18.07.19-ENGLISH-FINAL.pdf